Myleran (Busulfan)

Busulfan exerts its cytotoxic effect by alkylating the N7 position of guanine bases in DNA. This creates intra‑ and interstrand cross‑links that block DNA replication and transcription, ultimately triggering apoptosis in rapidly dividing cells, particularly malignant hematopoietic progenitors.

The specific dose of Myleran is individualized by the treating physician based on factors such as the patient’s weight, disease indication, and conditioning protocol. Dosing regimens are calculated to achieve target plasma concentrations while minimizing toxicity, and are not standardized in public literature.

Busulfan is classified as Pregnancy Category D, indicating evidence of fetal risk; it should be avoided in pregnant women. Limited data exist on excretion in breast milk, and because of potential toxicity to the infant, breastfeeding is generally contraindicated during treatment.

To request Myleran, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other alkylating agents such as cyclophosphamide, busulfan provides a more predictable myeloablative effect and is often combined with cyclophosphamide for synergistic activity. Unlike total body irradiation, busulfan is administered orally, offering convenience but requiring careful therapeutic drug monitoring to avoid over‑exposure.

Myleran capsules should be stored at ambient temperature, below 25 °C, in the original container to protect them from moisture and light. Do not refrigerate or freeze the product, and keep it out of reach of children.

Myleran is taken orally as capsules, usually divided into multiple doses over several days according to the prescribed conditioning schedule. The capsules should be swallowed whole with water and not crushed or chewed, unless directed otherwise by a healthcare professional.

The most serious adverse events linked to busulfan include pulmonary fibrosis, hepatic veno‑occlusive disease, and seizures. These complications can be life‑threatening and require close monitoring of lung and liver function, as well as prophylactic anticonvulsant therapy in high‑risk patients.

Myleran is contraindicated in patients with known hypersensitivity to busulfan or other alkylating agents, in pregnant women, and in individuals with severe hepatic or pulmonary impairment. Caution is also advised for patients with uncontrolled infections or significant renal dysfunction, and the drug should be avoided unless the benefits outweigh the risks.